KRAS, EGFR MUTATIONS AND EGFR GENE COPY STATUS AS PREDICTIVE MARKERS OF RESPONSE AND TIME TO PROGRESSION IN EGFR WILD-TYPE STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH EGFR TYROSINE-KINASE INHIBITORS.
JOURNAL OF THORACIC ONCOLOGY（2013）
Key words
Biomarkers,Tirosine-kinase inhibitors,NSCLC,metastatic
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined